Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Number 8—August 2025
Research
Rapid Emergence and Evolution of SARS-CoV-2 Intrahost Variants among COVID-19 Patients with Prolonged Infections, Singapore
Yvonne C.F. Su
, Michael A. Zeller, Peter Cronin, Rong Zhang, Yan Zhuang, Jordan Ma, Foong Ying Wong, Giselle G.K. Ng, Áine O’Toole, Andrew Rambaut, Jenny G. Low, and Gavin J.D. Smith
, Michael A. Zeller, Peter Cronin, Rong Zhang, Yan Zhuang, Jordan Ma, Foong Ying Wong, Giselle G.K. Ng, Áine O’Toole, Andrew Rambaut, Jenny G. Low, and Gavin J.D. Smith
Table 1
Epidemiologic and clinical characteristics of hospitalized patients in a study of rapid emergence and evolution of SARS-CoV-2 intrahost variants among COVID-19 patients with prolonged infections, Singapore*
| ID | Age,y/sex | BMI | Underlying conditions† | ICU admission | No. days hospitalized | Remdesivir treatment | Median lymphocyte count‡ | Median CRP, mg/L | Median leukocyte count‡ | Long-term medication | Pangolin lineage |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P1 | 29/F | 23.3 | N | N | 5 | N | 0.71 | 0 | 3.95 | N | B.6.6 |
| P2 | 48/M | 26.8 | N | N | 13 | Y | 2.28 | 18.5 | 5.93 | N | B.6 |
| P3 | 70/M | 22.5 | Y | Y | 40 | Y | 0.79 | 236.5 | 10.89 | Y | B.6.6 |
| P4 | 65/M | NA | Y | N | 30 | N | 1.22 | 51.2 | 6.89 | Y | B.6.6 |
| P5 | 67/F | 30.9 | N | N | 14 | Y | 1.05 | 122 | 4.61 | N | B.1.104 |
| P6 | 28/M | NA | N | N | 7 | N | 1.75 | 0 | 4.28 | N | B.6.3 |
| P7 | 64/M | 31.5 | Y | N | 16 | N | 2.32 | 12.6 | 5.09 | Y | B.6.6 |
| P8 | 29/M | 20.8 | N | N | 5 | N | 1.14 | 0 | 4.45 | N | B.6.6 |
| PP9 | 35/F | 21.6 | N | N | 7 | N | 1.44 | 0.9 | 4.66 | N | B.1.1 |
| P10 | 25/M | 21.7 | N | N | 11 | N | 1.45 | 0 | 3.80 | N | B.6.6 |
| P11 | 32/M | 27.3 | N | N | 4 | N | 0.87 | 0 | 7.00 | N | B.1.1 |
| P12 | 41/M | NA | N | N | 6 | N | 0.98 | 0 | 4.99 | N | B.6.6 |
| P13 | 37/M | 28.7 | N | N | 6 | N | 0.92 | 0 | 2.48 | N | B.6.6 |
| P14 | 34/F | NA | N | N | 5 | N | 1.82 | 0 | 5.29 | N | B.6.6 |
| P15 | 54/M | NA | N | N | 12 | N | 1.18 | 0.3 | 8.83 | N | B.6.6 |
| P16 | 21/F | NA | N | N | 8 | N | 1.31 | 31.9 | 4.98 | N | B.1.1 |
| P17 | 50/M | 31.8 | N | N | 3 | Y | 1.61 | 73 | 4.65 | N | B.6 |
| P18 | 37/M | NA | N | N | 5 | N | 3.31 | 0 | 6.89 | N | ND |
| P19 | 39/M | 14.7 | N | N | 5 | N | 0.74 | 0 | 3.73 | N | B.1.1 |
| P20 | 61/F | 25.8 | Y | Y | 30 | Y | 1.47 | 158 | 9.06 | Y | B.6 |
*BMI, body mass index; CRP, C-reactive protein; ICU, intensive care unit; ID, patient identification; ND, not determined; P, patient. †Including hypertension or hyperlipidemia. ‡Value × 109 cells/L.
Page created: May 31, 2025
Page updated: July 01, 2025
Page reviewed: July 01, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.